Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2023-10-19 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
SUPPLEMENTAL ANNOUNCEMENT
Board/Management Information Classification · 95% confidence The document is a supplemental announcement regarding the appointment of a joint company secretary, providing additional qualifications of the appointee. It references a previous announcement and clarifies compliance with listing rules. The content is about management information, specifically about a change or update in company secretary appointment. The document is short and does not contain financial data or detailed reports. Therefore, it fits the category of Board/Management Information (MANG).
2023-10-19 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2023
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 September 2023. It details movements in authorised and issued shares, share options, warrants, and other share-related schemes. It includes confirmations by a company director regarding compliance with listing rules and legal requirements. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital changes and share issuance activities for the month. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a regulatory filing reporting share capital movements and confirmations related to securities issuance. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (11666 characters) and detailed content support this classification with high confidence.
2023-10-03 English
CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG AND PROCESS AGENT
Board/Management Information Classification · 100% confidence The document is an announcement from the board of directors of Ocumension Therapeutics regarding a change in the company's principal place of business in Hong Kong and the appointment of a new process agent. It includes details about the change of address and the authorized representative for service of process. There is no financial data, no discussion of financial results, no mention of annual or interim reports, no voting results, no merger or acquisition activity, and no executive compensation details. The document is short (2051 characters) and is clearly an announcement of a corporate administrative change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management or related administrative changes.
2023-09-29 English
CHANGE OF JOINT COMPANY SECRETARIES AND AUTHORIZED REPRESENTATIVE
Board/Management Information Classification · 100% confidence The document is an announcement from Ocumension Therapeutics regarding changes in the company's joint company secretaries and authorized representative. It details resignations and new appointments of key company secretarial and governance personnel. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory filings beyond the announcement itself. The content focuses on management and board-related personnel changes, which fits the category of Board/Management Information (MANG). The document length is about 5,395 characters, which is consistent with a typical announcement of this nature rather than a full report.
2023-09-29 English
NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS
Report Publication Announcement Classification · 100% confidence The document is a notification letter dated September 27, 2023, from Ocumension Therapeutics to non-registered shareholders. It announces the publication of the company's 2023 Interim Report and provides instructions on how shareholders can access the report online or request printed copies. The letter explicitly states that the interim report is available on the company's and HKEX's websites and includes a request form for shareholders to receive future corporate communications. The document itself does not contain the interim report or substantive financial data but serves as a notice of publication and distribution method for the report. According to the 'MENU VS MEAL' rule, such a document is classified as a Report Publication Announcement (RPA) rather than the interim report itself.
2023-09-26 English
NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED SHAREHOLDERS
Report Publication Announcement Classification · 100% confidence The document is a notification letter dated September 27, 2023, from Ocumension Therapeutics informing shareholders about the publication of the 2023 Interim Report. It provides instructions on how shareholders can access the report electronically or request printed copies. The document does not contain the actual interim report or substantive financial data but serves as a notice of the report's availability on the company's and HKEX's websites. It also includes a change request form for shareholders to select their preferred method of receiving future corporate communications. Given the document's nature as a notification of report publication rather than the report itself, it fits the category of Report Publication Announcement (RPA).
2023-09-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.